Abstract
Human induced pluripotent stem (iPS) cells and human embryonic stem cells are cells that have the ability to differentiate into a variety of cell types. Embryonic stem cells are derived from human embryos; however, by contrast, human iPS cells can be obtained from somatic cells that have undergone a process of ‘reprogramming’ via genetic manipulation such that they develop pluripotency. Since iPS cells are not derived from human embryos, they are a less complicated source of human pluripotent cells and are considered valuable research tools and potentially useful in therapeutic applications in regenerative medicine. Worldwide, there are only three issued patents concerning iPS cells. Therefore, the patent landscape in this field is largely undefined. This article provides an overview of the issued patents as well as the pending published patent applications in the field.
Papers of special note have been highlighted as: ▪ of interest
Bibliography
- 1 Thomson JA, Itskovitz-Eldor J, Shapiro SS et al.: Embryonic stem cell lines derived from human blastocysts. Science282(5391),1145–1147 (1998).
- 2 Shamblott MJ, Axelman J, Wang S et al.: Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc. Natl Acad. Sci. USA95(23),13726–13731 (1998).
- 3 Gearhart J: A decade of stem-cell research. An interview with John Gearhart, Director of the Institute for Regenerative Medicine at the University of Pennsylvania, USA. Interview by Howard Wolinsky. EMBO Rep.10(1),12–16 (2009).
- 4 Takahashi K, Tanabe K, Ohnuki M et al.: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell131(5),861–872 (2007).
- 5 Yu J, Vodyanik MA, Smuga-Otto K et al.: Induced pluripotent stem cell lines derived from human somatic cells. Science318(5858),1917–1920 (2007).
- 6 Kang L, Wang J, Zhang Y, Kou Z, Gao S: IPS cells can support full-term development of tetraploid blastocyst-complemented embryos. Cell Stem Cell5(2),135–138 (2009).
- 7 Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K: Induced pluripotent stem cells generated without viral integration. Science322(5903),945–949 (2008).
- 8 Yu J, Hu K, Smuga-Otto K et al.: Human induced pluripotent stem cells free of vector and transgene sequences. Science324(5928),797–801 (2009).
- 9 Zhou H, Wu S, Joo JY et al.: Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell4(5),381–384 (2009).
- 10 Huangfu D, Osafune K, Maehr R et al.: Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat. Biotechnol.26(11),1269–1275 (2008).
- 11 Ichida JK, Blanchard J, Lam K et al.: A small-molecule inhibitor of TGF-β signaling replaces Sox2 in reprogramming by inducing Nanog. Cell Stem Cell5(5),491–503 (2009).
- 12 Webb S: The gold rush for induced pluripotent stem cells. Nat. Biotechnol.27(11),977–979 (2009).
- 13 United States Code (USC). Title 35: Patent Statute.
- 14 European Patent Office: Enlarged Board of Appeal of the European Patent Office decision. G0002/06, 26 November 2008.
- 15 Bilski v. Doll, 545 F.3d 943 (Fed.Cir. 2008), petition for writ of certiorari to the US Court of Appeals for the Federal Circuit granted, 129 S.Ct. 2735 (US 2009).
- 16 Ass’n for Molecular Pathology et al. v. US PTO et al., 2010 WL 1233416 (S.D.N.Y. 2010).▪ Important case as it found patent claims to isolated genes to be invalid.
- 17 Doi A, Park IH, Wen B et al.: Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet.41(12),1350–1353 (2009).
- 18 Chin MH, Mason MJ, Xie W et al.: Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell5(1),111–123 (2009).
- 19 Baker M: Stem cells: fast and furious. Nature458(7241),962–965 (2009).
- 20 SmithKline Beecham Corp. v. Apotex Corp., 439 F.3d 1312, 1319 (Fed.Cir. 2006).
- 21 Abbott Laboratories v. Sandoz, Inc., 566 F.3d 1282, 1293 (Fed.Cir. 2009).
- 22 Hwang WS, Ryu YJ, Park JH et al.: Evidence of a pluripotent human embryonic stem cell line derived from a cloned blastocyst. Science303(5664),1669–1674 (2004).
- 23 Kennedy D: Editorial retraction. Science311(5759),335 (2006).
- 24 Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co., 560 F.3d 1366 (Fed.Cir. 2009), petition for reh’g granted, 332 Fed.Appx. 636 (Fed.Cir. 2009).
- 25 Park IH, Zhao R, West JA et al.: Reprogramming of human somatic cells to pluripotency with defined factors. Nature451(7175),141–146 (2008).
- 26 Hanna J, Markoulaki S, Schorderet P et al.: Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell133(2),250–264 (2008).
- 101 Wisconsin Alumni Research Foundation: US5843780C1 (2008).
- 102 Wisconsin Alumni Research Foundation: US6200806C1 (2008).
- 103 Jaenisch R, Hochedlinger K: US7682828 (2010).▪ Important patent as it is one of only three issued patents with claims regarding induced pluripotent stem (iPS) cells.
- 104 Sakurada K, Masaki H, Ishikawa T, Takahashi S: GB2450603 (2010).▪ Important patent as it is one of only three issued patents with claims regarding iPS cells.
- 105 iZumi Bio, Inc.: WO2009006930 (2009).
- 106 iZumi Bio, Inc.: WO2009006997 (2009).
- 107 iZumi Bio, Inc.: WO2009007852 (2009).
- 108 Sakurada K, Masaki H, Ishikawa T, Takahashi S: US20090191159 (2009).
- 109 Sakurada K: US20090299763 (2009).
- 110 Sakurada K, Masaki H, Ishikawa T, Takahashi S: US20090304646 (2009).
- 111 Sakurada K, Seidenman KJ: US20090324559 (2009).
- 112 Yamanaka S: JP04183742 (2008).▪ Important patent as it is one of only three issued patents with claims regarding iPS cells.
- 113 Yamanaka S: US20090068742 (2009).
- 114 Yamanaka S, Takahashi K, Nakagawa M: US20090047263 (2009).
- 115 Yamanaka S, Takahashi K; Nakagawa M: US20090227032 (2009).
- 116 Yamanaka S, Koyanagi M: US20090246875 (2009).
- 117 Thomson J, Yu J: US20080233610; WO2008118820 (2008).
- 118 Mack A, Thomson J: US20100003757 (2010).
- 119 Helmholtz Zentrum München – Deutsches Forschungszentrum für Gesundheit und Umwelt (GMBH): WO2009115295 (2009).
- 120 Nevada Cancer Institute: WO2009092042 (2009).
- 121 The Scripps Research Institute: WO2009117439 (2009).
- 122 President and Fellows of Harvard College: WO2009102983 (2009).
- 123 Mirae Biotech Co., Ltd.: WO2009096614 (2009).
- 124 Children’s Medical Center Corporation: WO2009061442 (2009).
- 125 Whitehead Institute for Biomedical Research: WO2009032194 (2009).
- 126 Whitehead Institute for Biomedical Research: WO2008124133 (2008).
- 127 The General Hospital Corporation: WO2008151058 (2008).
- 128 Primegen Biotech LLC: WO2009032456 (2009).
- 129 Jonannes Gutenberg-Universitat Mainz: WO2009077134 (2009).
- 130 Lin S, Ying S, Wu DTs: US20080293143 (2008).
- 131 Wisconsin Alumni Research Foundation: US7029913 (2006).
- 201 Executive Order of March 9, 2009: Removing barriers to responsible scientific research involving human stem cells, 74 Federal Register 10667 11 March (2009) www.archives.gov/federal-register/executive-orders/2009-obama.html
- 202 NIH Guidelines for Human Stem Cells Research, 2009 http://stemcells.nih.gov/policy/2009guidelines.htm
- 203 Section 509, Omnibus Appropriation Act, 2010, HR3288.ENR. Pub. L. 111–117, December 16, 2009; known as the Dickey-Wicker Amendment, re-enacted annually by Congress, original rider can be found in Section 128 of PL 104–199, 110 Stat. 26, 34 (1996) http://thomas.loc.gov/cgi-bin/bdquery/D?d111:3:./temp/∼bdjTyD::|/home/LegislativeData.php|
- 204 Stein R: US set to fund more stem cell study www.washingtonpost.com/wp-dyn/content/article/2009/12/02/AR2009120201955.html